Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Sigilon Therapeutics Inc is a biotechnology business based in the US. Sigilon Therapeutics shares (SGTX) are listed on the NASDAQ and all prices are listed in US Dollars. Sigilon Therapeutics employs 99 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Guided Investing
Our top pick for
Experienced Investors
| Latest market close | $5.55 |
|---|---|
| 52-week range | $4.33 - $54.32 |
| 50-day moving average | $5.69 |
| 200-day moving average | $9.44 |
| Wall St. target price | $20.75 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-3.32 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $5.55 from 2021-10-15
| 1 week (2021-10-11) | 4.91% |
|---|---|
| 1 month (2021-09-17) | -9.17% |
| 3 months (2021-07-16) | -6.25% |
| 6 months (2021-04-16) | -67.43% |
| 1 year (2020-10-14) | N/A |
|---|---|
| 2 years (2019-10-14) | N/A |
| 3 years (2018-10-14) | N/A |
| 5 years (2016-10-14) | N/A |
| Revenue TTM | $13.6 million |
|---|---|
| Gross profit TTM | $-40,114,000 |
| Return on assets TTM | -29.89% |
| Return on equity TTM | -107.52% |
| Profit margin | 0% |
| Book value | $3.49 |
| Market capitalisation | $177.9 million |
TTM: trailing 12 months
There are currently 777,389 Sigilon Therapeutics shares held short by investors – that's known as Sigilon Therapeutics's "short interest". This figure is 1% up from 769,355 last month.
There are a few different ways that this level of interest in shorting Sigilon Therapeutics shares can be evaluated.
Sigilon Therapeutics's "short interest ratio" (SIR) is the quantity of Sigilon Therapeutics shares currently shorted divided by the average quantity of Sigilon Therapeutics shares traded daily (recently around 217147.76536313). Sigilon Therapeutics's SIR currently stands at 3.58. In other words for every 100,000 Sigilon Therapeutics shares traded daily on the market, roughly 3580 shares are currently held short.
To gain some more context, you can compare Sigilon Therapeutics's short interest ratio against those of similar companies.
However Sigilon Therapeutics's short interest can also be evaluated against the total number of Sigilon Therapeutics shares, or, against the total number of tradable Sigilon Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sigilon Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Sigilon Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.053% of the tradable shares (for every 100,000 tradable Sigilon Therapeutics shares, roughly 53 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Sigilon Therapeutics.
Find out more about how you can short Sigilon Therapeutics stock.
We're not expecting Sigilon Therapeutics to pay a dividend over the next 12 months.
Sigilon Therapeutics, Inc. , a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 designed to replace islet cells for the treatment of type 1 diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.